Geron Corporation [NASDAQ: GERN] stock went on an upward path that rose over 2.01% on Tuesday, amounting to a one-week price increase of more than 3.05%. The company report on October 2, 2020 that Geron Secures Loan Facility for Up to $75 Million.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it has entered into a loan facility for up to $75 million with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank (SVB). The loan facility provides the Company with access to non-dilutive financial resources to support the imetelstat development program, as well as working capital and general corporate purposes.
“This debt financing strengthens our balance sheet and provides additional financial flexibility as our imetelstat program advances with two Phase 3 registration-enabling clinical trials – the ongoing IMerge trial in lower risk myelodysplastic syndromes and the planned trial in refractory myelofibrosis,” said Olivia K. Bloom, Chief Financial Officer. “We look forward to working with Hercules and SVB in the future as we include non-dilutive capital in our financing strategy.”.
Over the last 12 months, GERN stock rose by 39.04%. The average equity rating for GERN stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $627.07 million, with 310.47 million shares outstanding and 260.39 million shares in the current float. Compared to the average trading volume of 2.95M shares, GERN stock reached a trading volume of 3357536 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Geron Corporation [GERN]:
Stifel have made an estimate for Geron Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 03, 2020. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on November 19, 2019, representing the official price target for Geron Corporation stock. Previously, the target price had yet another raise to $4, while H.C. Wainwright analysts kept a Buy rating on GERN stock.
The Average True Range (ATR) for Geron Corporation is set at 0.11, with the Price to Sales ratio for GERN stock in the period of the last 12 months amounting to 1567.67. The Price to Book ratio for the last quarter was 1.99, with the Price to Cash per share for the same quarter was set at 0.71.
GERN Stock Performance Analysis:
Geron Corporation [GERN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.05. With this latest performance, GERN shares gained by 2.01% in over the last four-week period, additionally plugging by 70.59% over the last 6 months – not to mention a rise of 39.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GERN stock in for the last two-week period is set at 62.72, with the RSI for the last a single of trading hit 66.02, and the three-weeks RSI is set at 58.28 for Geron Corporation [GERN]. The present Moving Average for the last 50 days of trading for this stock 1.81, while it was recorded at 2.01 for the last single week of trading, and 1.54 for the last 200 days.
Insight into Geron Corporation Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Geron Corporation [GERN] shares currently have an operating margin of -15761.96. Geron Corporation’s Net Margin is presently recorded at -14901.74.
Return on Total Capital for GERN is now -45.97, given the latest momentum, and Return on Invested Capital for the company is -43.51. Return on Equity for this stock declined to -43.82, with Return on Assets sitting at -39.08. When it comes to the capital structure of this company, Geron Corporation [GERN] has a Total Debt to Total Equity ratio set at 1.89. Additionally, GERN Total Debt to Total Capital is recorded at 1.85, with Total Debt to Total Assets ending up at 1.54. Long-Term Debt to Equity for the company is recorded at 1.63, with the Long-Term Debt to Total Capital now at 1.60.
Reflecting on the efficiency of the workforce at the company, Geron Corporation [GERN] managed to generate an average of -$1,490,174 per employee. Receivables Turnover for the company is 0.47 with a Total Asset Turnover recorded at a value of 0.00.Geron Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.50 and a Current Ratio set at 11.50.
GERN Stock EPS
With the latest financial reports released by the company, Geron Corporation posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.15/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 46.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GERN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Geron Corporation go to 5.00%.
Geron Corporation [GERN] Insider Position Details
There are presently around $318 million, or 53.80% of GERN stock, in the hands of institutional investors. The top three institutional holders of GERN stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 30,126,299, which is approximately New of the company’s market cap and around 0.41% of the total institutional ownership; BLACKROCK INC., holding 19,400,364 shares of the stock with an approximate value of $39.38 million in GERN stocks shares; and ECOR1 CAPITAL, LLC, currently with $39.04 million in GERN stock with ownership of nearly New of the company’s market capitalization.
Positions in Geron Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 76 institutional holders increased their position in Geron Corporation [NASDAQ:GERN] by around 97,314,275 shares. Additionally, 31 investors decreased positions by around 2,287,690 shares, while 42 investors held positions by with 56,970,432 shares. The mentioned changes placed institutional holdings at 156,572,397 shares, according to the latest SEC report filing. GERN stock had 30 new institutional investments in for a total of 82,610,473 shares, while 8 institutional investors sold positions of 440,657 shares during the same period.